{"filings":[{"id":78162,"accession_number":"0001193125-26-222908","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2026-05-14T12:31:16+00:00","items":["1.01","2.01","2.03","7.01","9.01"],"status":"ready","headline":"Biogen completes $5.3B Apellis acquisition; adds SYFOVRE/EMPAVELI, $41/share + CVRs","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Biogen acquired Apellis for $41/share cash plus CVRs worth up to $4/share tied to SYFOVRE net sales milestones.","Approximately 105.7M shares (82.4%) tendered; Merger completed under DGCL Section 251(h) without shareholder vote.","Biogen borrowed $2B under a new credit agreement: $1B 364-day and $1B 2-year tranches to fund the acquisition.","Apellis products EMPAVELI and SYFOVRE generated $689M net product revenue in 2025; deal expected to be accretive to Non-GAAP EPS in 2027.","Biogen will provide updated financial guidance in Q2 2026 earnings report in July."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99329,"accession_number":"0000875045-26-000042","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen Q1 revenue $2.5B, EPS beat; proposes Apellis acquisition, updates FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 rev $2.5B (+2% YoY); GAAP EPS $2.15 (+31%); Non-GAAP EPS $3.57 (+18%).","Growth products: LEQEMBI $168M (+74%), SKYCLARYS $151M (+22%), ZURZUVAE $55M (+100%), VUMERITY $179M (+29%), QALSODY $33M (+110%).","Proposed Apellis acquisition expected to close Q2 2026, accretive in 2027; Biogen to update guidance post-close.","FY2026 Non-GAAP EPS guidance $14.25-$15.25 (ex-Apellis); total revenue seen declining mid-single digit % vs 2025.","Pipeline: litifilimab Phase 2 CLE positive; SPINRAZA High Dose Regimen FDA approved; felzartamab rights in Greater China acquired."],"consensus_eps_estimate":2.8258,"consensus_eps_actual":2.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":2477800000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99328,"accession_number":"0000875045-26-000039","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2026-04-06T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Biogen warns of $34M pre-tax IPR&D and upfront charge in Q1 2026, impacting EPS by $0.19","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Preliminary estimate: ~$34M pre-tax acquired in-process R&D, upfront and milestone expense for Q1 2026.","Expected to reduce GAAP and non-GAAP diluted EPS by approximately $0.19 per share.","Expense includes upfront/milestone payments and premiums on equity securities related to collaboration and license agreements.","Biogen does not forecast such costs due to uncertainty; final Q1 results not yet finalized and may differ."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115266,"accession_number":"0001193125-26-134889","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Biogen to acquire Apellis for $41/share plus up to $4 CVR per share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash consideration of $41.00 per Apellis share; one CVR per share entitling holders to up to $4.00 additional.","CVR milestones: $2.00 if SYFOVRE annual net sales reach $1.5B; $2.00 if $2.0B achieved, with potential $4.00 single payment.","Tender offer condition requires >50% shares tendered; termination fee of $205M payable by Apellis in certain circumstances.","Stockholders representing ~14% of Apellis shares entered support agreement to tender in favor.","Transaction expected to close by September 30, 2026, subject to regulatory approvals and other conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115265,"accession_number":"0000950157-26-000280","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Biogen Chief Legal Officer Susan H. Alexander to depart end of May 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Susan H. Alexander, Chief Legal Officer, will leave Biogen effective end of May 2026.","Company has initiated a search to identify the next Chief Legal Officer.","No interim successor has been named at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115264,"accession_number":"0001193125-26-046803","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Biogen Chair Caroline Dorsa to step down; Dr. Maria C. Freire elected as new Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chair Caroline Dorsa will not stand for re-election at the 2026 Annual Meeting; decision unrelated to any disagreement.","Board elected Dr. Maria C. Freire to serve as Chair, effective after the Annual Meeting.","Dr. Freire's appointment marks an orderly transition of Board leadership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115263,"accession_number":"0000875045-26-000011","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen Q4 revenue $2.3B, GAAP EPS loss $(0.33); FY2025 Non-GAAP EPS $15.28 beats guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $2.3B (-7% YoY); GAAP diluted EPS $(0.33); Non-GAAP diluted EPS $1.99.","Full year total revenue $9.9B (+2% YoY); GAAP diluted EPS $8.79; Non-GAAP EPS $15.28 above $14.50-$15.00 guidance.","Growth products up 6% YoY in Q4; LEQEMBI global in-market sales $134M (+54% YoY).","FY2026 guidance: Non-GAAP diluted EPS $15.25-$16.25; total revenue to decline mid-single digit percent vs FY2025.","Pipeline: LEQEMBI subcutaneous PDUFA May 24, 2026; litifilimab Breakthrough Therapy for CLE; high-dose SPINRAZA PDUFA Apr 3."],"consensus_eps_estimate":1.6464,"consensus_eps_actual":8.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":9890600000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115262,"accession_number":"0000875045-26-000003","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Biogen expects ~$222M pre-tax charge in Q4 2025 for IPR&D and milestone costs; EPS impact ~$1.26","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 acquired IPR&D, upfront and milestone expense estimated at ~$222M pre-tax.","Estimated impact of $1.26 per diluted share on both GAAP and non-GAAP EPS.","Expense line item newly presented separately since Q1 2025.","Final Q4 2025 results not finalized; subject to closing procedures.","Company does not forecast such expenses due to uncertainty in timing and magnitude."],"consensus_eps_estimate":1.6464,"consensus_eps_actual":8.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":9890600000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131682,"accession_number":"0000875045-25-000047","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen Q3 revenue $2.5B (+3% YoY); non-GAAP EPS $4.81 (+18%); FY25 guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $3.17 (+19% YoY); Non-GAAP diluted EPS $4.81 (+18% YoY).","Launch products LEQEMBI ($121M, +82%), SKYCLARYS ($133M, +30%), ZURZUVAE ($55M) all show strong growth.","Full year 2025 revenue guidance raised to flat to +1% (constant currency); Non-GAAP EPS guided $14.50-$15.00.","Pipeline: LEQEMBI IQLIK approved, high-dose nusinersen resubmitted (PDUFA Apr'26), litifilimab Phase 3 fully enrolled (data H2'26)."],"consensus_eps_estimate":3.9595,"consensus_eps_actual":9.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":7611200000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131681,"accession_number":"0000875045-25-000040","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen expects ~$2M pre-tax IPR&D charge for Q3, impact of ($0.01)/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary estimate: acquired IPR&D, upfront & milestone expense of ~$2M pre-tax.","Estimated impact of ($0.01) per diluted share on both GAAP and non-GAAP EPS.","Q3 2025 results not yet finalized; subject to closing procedures and could differ."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148250,"accession_number":"0000875045-25-000035","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen Q2 revenue $2.6B (+7% YoY), GAAP EPS $4.33, raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 revenue $2.6B (+7% YoY); GAAP EPS $4.33 (+8%); Non-GAAP EPS $5.47 (+4%).","Raised FY2025 Non-GAAP EPS guidance to $15.50-$16.00 (from $14.50-$15.50); revenue now expected ~flat vs 2024.","LEQEMBI U.S. in-market sales ~$63M (+20% sequential); global ~$160M incl. $35M one-time China shipment.","SKYCLARYS global rev. ~$130M; U.S. ~$78M (+13% seq.); ZURZUVAE $46M (+68% seq.).","Pipeline: salanersen advancing to registrational stage in SMA; felzartamab Phase 3 initiated in rare kidney diseases."],"consensus_eps_estimate":3.9375,"consensus_eps_actual":5.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":5076500000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148249,"accession_number":"0000875045-25-000027","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen expects Q2 2025 charge of $46M for IPR&D, reducing EPS by ~$0.26","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pre-tax acquired IPR&D, upfront and milestone expense of ~$46M in Q2 2025.","GAAP and non-GAAP diluted EPS impact of approximately ($0.26) per share.","Charge covers upfront and milestone payments from collaboration/license agreements.","Biogen does not forecast such expenses due to uncertainty in timing and magnitude.","Q2 2025 results not finalized; subject to closing procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167020,"accession_number":"0000875045-25-000023","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Biogen stockholders elect all 11 director nominees, ratify auditor, approve say-on-pay at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 11 nominees elected to one-year terms; Caroline Dorsa received the most votes against (25.5M).","Ratification of PwC as auditor for FY 2025 passed with 120.1M for, 5.9M against.","Say-on-pay advisory vote approved with 78.5M for, 37.1M against (68% approval excluding broker non-votes).","Meeting held June 17, 2025; results reflect standard governance items without any contested matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167019,"accession_number":"0001193125-25-117854","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biogen issues $1.75B in three tranches of senior notes to refinance maturing 2025 debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$400M 5.050% notes due 2031, $650M 5.750% notes due 2035, $700M 6.450% notes due 2055.","Net proceeds, with cash on hand, will retire the outstanding $1.75B 4.050% Senior Notes due 2025.","Notes are senior unsecured; redeemable at par plus make-whole; 101% change-of-control put.","Underwriters: BofA Securities, Citigroup Global Markets, J.P. Morgan Securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167018,"accession_number":"0000875045-25-000014","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen Q1 revenue up 6% to $2.43B; Non-GAAP EPS $3.02 impacted by $165M Stoke upfront","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $1.64, Non-GAAP $3.02; both down YoY due to ~($0.95) impact from Stoke upfront payment.","LEQEMBI global in-market sales ~$96M; SKYCLARYS global revenue ~$124M; launch products more than doubled YoY.","Updated FY2025 non-GAAP EPS guidance $14.50-$15.50; total revenue expected to decline mid-single-digit constant currency.","Felzartamab Phase 3 study initiated in antibody-mediated rejection; BIIB080 (tau ASO) received FDA Fast Track designation.","Zorevunersen collaboration with Stoke ($165M upfront) for Dravet syndrome; pivotal Phase 3 to start in coming months."],"consensus_eps_estimate":null,"consensus_eps_actual":1.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":2431000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184399,"accession_number":"0000875045-25-000004","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen Q4 revenue up 3% to $2.5B, non-GAAP EPS $3.44; FY2025 guidance calls for revenue decline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $2.5B (+3% YoY); GAAP EPS $1.83, non-GAAP EPS $3.44 (+17% YoY).","Full year 2024 revenue $9.7B (-2% YoY); non-GAAP EPS $16.47 (+12% YoY).","LEQEMBI global in-market sales ~$87M; SKYCLARYS revenue ~$102M, patient count nearly doubled vs end 2023.","Regulatory milestones: LEQEMBI subcutaneous BLA accepted (PDUFA Aug 31, 2025); nusinersen higher dose filings accepted (PDUFA Sep 22, 2025).","FY2025 guidance: non-GAAP diluted EPS $15.25-$16.25; total revenue to decline mid-single digit % at constant currency."],"consensus_eps_estimate":null,"consensus_eps_actual":11.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":9675900000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184398,"accession_number":"0001193125-25-006578","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Biogen appoints Sean Godbout as Chief Accounting Officer effective March 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sean Godbout to succeed Robin Kramer as CAO and principal accounting officer; Kramer transitions to CFO role upon McDonnell's retirement.","Michael McDonnell to retire as CFO on March 1, 2025; Kramer previously announced as successor.","Godbout, age 50, internal promotion from Global Corporate Controller (since Oct 2023), joined Biogen in 2007.","Base salary $400,000; annual bonus target 40% of base; eligible for long-term incentive grants and executive severance plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200998,"accession_number":"0001193125-24-247628","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Biogen CFO Michael McDonnell to retire Feb 2025; Robin Kramer named successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael McDonnell to retire as CFO effective February 28, 2025, after serving since August 2020.","Robin Kramer, current Chief Accounting Officer, appointed CFO effective upon McDonnell's retirement.","Kramer's base salary $750,000; target bonus 80% of base; 2025 target LTI grant $3.75 million.","Kramer joined Biogen in 2018, served as CAO since 2020, also leads Treasury, procurement, and global business services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200997,"accession_number":"0000875045-24-000030","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen Q3 GAAP EPS $2.66, revenue $2.466B; raises FY2024 Non-GAAP EPS guidance to $16.10-$16.60","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 revenue $2.466B (-3% YoY); GAAP diluted EPS $2.66 vs ($0.47) in Q3 2023.","Non-GAAP diluted EPS $4.08 (-6% YoY); FY2024 Non-GAAP EPS guidance raised to $16.10-$16.60 (~11% growth at midpoint).","LEQEMBI global in-market sales ~$67M (US $39M); other launches delivered sequential revenue growth.","Dapirolizumab pegol Phase 3 met primary endpoint in SLE; second Phase 3 study to initiate in 2024.","Nusinersen higher dose showed statistically significant improvement; global regulatory submissions planned."],"consensus_eps_estimate":null,"consensus_eps_actual":9.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":7221200000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217005,"accession_number":"0001193125-24-217633","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Biogen elects Dr. Lloyd Minor and Prof Sir Menelas Pangalos to Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased; Dr. Lloyd Minor effective Oct 1, 2024; Prof Sir Mene Pangalos effective Jan 1, 2025.","Both directors serve until 2025 Annual Meeting; receive standard non-employee director compensation.","Each will enter into indemnification agreement on same terms as other directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217004,"accession_number":"0001193125-24-200660","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Biogen enters $1.5B unsecured revolving credit facility, terminates prior facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$1.5B five-year unsecured revolving credit facility; no borrowings drawn at closing.","Replaces 2020 credit agreement; no outstanding loans at termination.","Interest rates based on credit ratings: Term SOFR + 0.625%-1.375%; commitment fee 0.05%-0.15%.","Financial covenant: max consolidated leverage ratio of 3.75:1 (4.25:1 after material acquisition).","Matures August 2029, includes $25M letter of credit sublimit, $20M swing line."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217003,"accession_number":"0000875045-24-000022","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen Q2 revenue flat at $2.47B; Non-GAAP EPS up 31% to $5.28; raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $2,465M flat YoY; GAAP diluted EPS $4.00 (-2%), Non-GAAP diluted EPS $5.28 (+31%).","Core pharma revenue up 5% actual/6% CC; LEQEMBI global in-market sales ~$40M (US ~$30M).","SKYCLARYS rev $100M, ZURZUVAE rev $15M; completed HI-Bio acquisition expanding immunology pipeline.","Raised FY2024 Non-GAAP EPS guidance to $15.75-$16.25 (mid-point ~9% growth vs FY2023).","Retains Biosimilars business; expects operating income growth mid- to high-teen % and margin improvement."],"consensus_eps_estimate":null,"consensus_eps_actual":6.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":4755400000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236759,"accession_number":"0001193125-24-167938","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Biogen shareholders approve officer exculpation amendment and elect nine directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Certificate of Amendment filed to allow officer exculpation to extent permitted by Delaware law; approved with 103.1M votes for, 16.3M against.","All nine director nominees elected with wide margins; Monish Patolawala received 119.1M votes for, highest count.","Ratification of PwC as independent auditor for FY2024: 123.7M for, 5.3M against.","Advisory vote on executive compensation passed with 114.4M for, 5.1M against.","Adoption of 2024 Omnibus Equity Plan and 2024 Employee Stock Purchase Plan both approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}